Skip to main content
. 2018 Feb 2;36(5):591–601. doi: 10.1007/s40273-017-0604-3

Fig. 4.

Fig. 4

Cost-effectiveness acceptability frontier for genotype 3. PEG peginterferon-α-2a, RBV ribavirin, SOF sofosbuvir, PR PEG + RBV, QALY quality-adjusted life-year